Reducing diabetes medications in geriatric patients with low A1c involves careful consideration of the risks and benefits of continued intensive glycemic control. In older adults, particularly those with multiple comorbidities, frailty, or limited life expectancy,...
Insulin icodec may have a new competitor in the near future. Insulin efsitora is another once-weekly insulin currently undergoing phase 3 clinical trials, with Lilly’s 3rd phase being termed the QWINT trials (Once Weekly (QW) Insulin Therapy (INT)). These trials are...
Fluctuations in blood sugars can be very distressing for patients. This is especially true in patients who have adequate control of their diabetes. Adverse effects can lead to an escalation of diabetes medication. I’ll share my top 5 drugs that cause...
For individuals with type 2 diabetes taking insulin, managing doses is a critical aspect of their treatment regimen. Proper management of insulin doses can help maintain blood sugar levels within a healthy range and prevent complications associated with high or low...
The 2024 ADA guidelines were released a month or two ago and I wanted to take a little time to digest them before providing my big takeaways. The 2023 guidelines saw a major shift in pharmacotherapy with a strong emphasis on compelling indications and recommended...
